切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2017, Vol. 06 ›› Issue (02) : 134 -138. doi: 10.3877/cma.j.issn.2095-3232.2017.02.014

所属专题： 文献；

基础研究

STEAP3对肝癌细胞增殖能力的抑制作用及机制
范伟明1, 姚志成2, 徐见亮1, 熊志勇2, 李瑞曦1, 周伯宣1, 邓美海1,†()   
  1. 1. 510630　广州，中山大学附属第三医院肝胆外科
    2. 510530　广州，中山大学附属第三医院岭南医院普通外科
  • 收稿日期:2016-11-26 出版日期:2017-04-10
  • 通信作者: 邓美海
  • 基金资助:
    国家自然科学基金(81572726); 广东省科技计划项目(2014A020212122); 广东省医学科研基金(A2016312); 广州市科技计划项目(1563000226)

Effect and mechanism of STEAP3 on inhibiting the proliferation ability of hepatocellular carcinoma cells

Weiming Fan1, Zhicheng Yao2, Jianliang Xu1, Zhiyong Xiong2, Ruixi Li1, Boxuan Zhou1, Meihai Deng1,†()   

  1. 1. Department of Hepatobiliary Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
    2. Department of General Surgery, Lingnan Hospital, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510530, China
  • Received:2016-11-26 Published:2017-04-10
  • Corresponding author: Meihai Deng
  • About author:
    Corresponding author: Deng Meihai, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

范伟明, 姚志成, 徐见亮, 熊志勇, 李瑞曦, 周伯宣, 邓美海. STEAP3对肝癌细胞增殖能力的抑制作用及机制[J]. 中华肝脏外科手术学电子杂志, 2017, 06(02): 134-138.

Weiming Fan, Zhicheng Yao, Jianliang Xu, Zhiyong Xiong, Ruixi Li, Boxuan Zhou, Meihai Deng. Effect and mechanism of STEAP3 on inhibiting the proliferation ability of hepatocellular carcinoma cells[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2017, 06(02): 134-138.

目的

探讨前列腺六次跨膜蛋白（STEAP3）对肝癌细胞增殖能力的抑制作用及机制。

方法

构建稳定干扰表达STEAP3的肝癌细胞株7721-shSTEAP3、QGY-shSTEAP3（干扰组），及其对照细胞株7721-VECTOR、QGY-VECTOR（对照组）。采用RT-PCR检测STEAP3 mRNA的表达，CCK-8法检测细胞增殖能力，流式细胞仪检测细胞周期，Western blot检测细胞周期相关蛋白的表达。实验数据比较采用t检验。

结果

成功构建稳定干扰表达STEAP3的肝癌细胞株，干扰组7721-shSTEAP3和QGY-shSTEAP3细胞的STEAP3 mRNA表达量分别为（5.10±0.70）×10-3和（0.09±0.02）×10-3，明显低于对照组7721-VECTOR和QGY-VECTOR细胞的（7.80±0.07）×10-3和（7.00±0.21）×10-3（t=-9.60，-57.16；P<0.05）。细胞生长曲线显示干扰组7721-shSTEAP3和QGY-shSTEAP3细胞的增殖能力明显强于对照组7721-VECTOR和QGY-VECTOR细胞。细胞周期检测结果显示干扰组7721-shSTEAP3和QGY-shSTEAP3细胞的G0/G1期分别为（55.23±0.51）%、（57.38±0.78）%，明显低于对照组7721-VECTOR和QGY-VECTOR细胞的（68.25±0.28）%、（77.55±0.89）%（t=-7.83，-27.39；P<0.05）。干扰组7721-shSTEAP3和QGY-shSTEAP3细胞的细胞周期蛋白（cyclin）D1、细胞周期蛋白依赖激酶（CDK）4蛋白表达水平分别为0.730±0.017、1.090±0.028和0.780±0.063、1.310±0.031，明显高于对照组7721-VECTOR和QGY-VECTOR细胞的0.660±0.059、0.780±0.085和0.530±0.014、0.920±0.024 （t=4.47，6.87和12.33，4.89；P<0.05）。

结论

STEAP3具有抑制肝癌细胞增殖能力的作用，其机制可能与G1期细胞周期阻滞有关。

关键词: 蛋白质类, 肝肿瘤, 细胞增殖, 细胞周期
Objective

To investigate the effect and mechanism of six transmembrane epithelial antigen prostate 3 (STEAP3) on inhibiting the proliferation of hepatocellular carcinoma (HCC) cells.

Methods

HCC cell lines 7721-shSTEAP3 and QGY-shSTEAP3 expressing STEAP3 were stably interfered in the interference group. And the control cells 7721-VECTOR and QGY-VECTOR were also established in the control group. The expression of STEAP3 mRNA was detected by RT-PCR. The proliferation ability of the cells was detected by CCK-8 assay. Cell cycle was detected by flow cytometry. The expression of cell cycle-associated proteins were detected by Western blot. The experimental data were compared using t test.

Results

HCC cell lines expressing STEAP3 were stably interfered successfully. The expression levels of STEAP3 mRNA in the 7721-shSTEAP3 and QGY-shSTEAP3 cells of the interference group were respectively (5.10±0.70)×10-3 and (0.09±0.02)×10-3, significantly lower than (7.80±0.07)×10-3 and (7.00±0.21)×10-3 in the 7721-VECTOR and QGY-VECTOR cells of the control group (t=-9.60, -57.16; P<0.05). Cell growth curve showed that the proliferation ability of 7721-shSTEAP3 and QGY-shSTEAP3 cells in the interference group were significantly enhanced compared with that of 7721-VECTOR and QGY-VECTOR cells in the control group. Cell cycle detection showed that (55.23±0.51)% and (57.38±0.78)% of 7721-shSTEAP3 and QGY-shSTEAP3 cells in the interference group were in G0/G1 phase, significantly lower than (68.25±0.28)% and (77.55±0.89)% of 7721-VECTOR and QGY-VECTOR cells in the control group (t= -7.83, -27.39; P<0.05). The expression levels of cyclin D1 and protein cyclin-dependent kinase 4 (CDK4) of the 7721-shSTEAP3 and QGY-shSTEAP3 cells in the interference group were respectively 0.730±0.017, 1.090±0.028 and 0.780±0.063, 1.310±0.031, significantly higher than 0.660±0.059, 0.780±0.085 and 0.530±0.014, 0.920±0.024 of the 7721-VECTOR and QGY-VECTOR cells in the control group (t=4.47, 6.87 and 12.33, 4.89; P<0.05).

Conclusions

STEAP3 exerts an effect on inhibiting the proliferation ability of HCC cells. The mechanism may probably be correlated with blocking the G1 phase of cell cycle.

Key words: Proteins, Liver neoplasms, Cell proliferation, Cell cycle
图1 干扰组和对照组细胞各时间点的生长曲线
图2 Western blot检测STEAP3对肝癌细胞周期相关蛋白表达水平的影响
[1]
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
[2]
Forner A, Reig M, Varela M, et al. Diagnosis and treatment of hepatocellular carcinoma. update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH[J]. Med Clin, 2016, 146(11):511.
[3]
周开梅，郭瑞珍．细胞周期蛋白在恶性肿瘤中的表达[J]．医学综述，2010，16(4):533-536.
[4]
Passer BJ, Nancy-Portebois V, Amzallag N, et al. The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase[J]. Proc Natl Acad Sci U S A, 2003, 100(5):2284-2289.
[5]
Caillot F, Daveau R, Daveau M, et al. Down-regulated expression of the TSAP6 protein in liver is associated with a transition from cirrhosis to hepatocellular carcinoma[J]. Histopathology, 2009, 54(3):319-327.
[6]
周业庭，吴柏华，徐本文，等．PI3Kp110beta和前强啡肽在人肝癌组织中的表达[J]．中华实验外科杂志，2008，25(11):1399-1400.
[7]
Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors[J]. Proc Natl Acad Sci U S A, 1999, 96(25):14523-14528.
[8]
Ihlaseh-Catalano SM, Drigo SA, de Jesus CM, et al. STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma[J]. Histopathology, 2013, 63(5):678-685.
[9]
Isobe T, Baba E, Arita S, et al. Human STEAP3 maintains tumor growth under hypoferric condition[J]. Exp Cell Res, 2011, 317(18):2582-2591.
[10]
韩世愈，王娇．细胞周期蛋白在恶性肿瘤中的表达及其在肿瘤治疗中的作用[J]．分子诊断与治疗杂志，2013(5):357-360.
[11]
Güller M, Toualbi-Abed K, Legrand A, et al. c-Fos overexpression increases the proliferation of human hepatocytes by stabilizing nuclear Cyclin D1[J]. World J Gastroenterol, 2008, 14(41):6339-6346.
[12]
Lee TK, Man K, Poon RT, et al. Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma[J]. Oncol Rep, 2004, 12(1):25-31.
[13]
Wang C, Li Z, Fu M, et al. Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential[J]. Cancer Treat Res, 2004(119):217-237.
[14]
Lee CC, Yamamoto S, Wanibuchi H, et al. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation[J]. Cancer Res, 1997, 57(21):4765-4776.
[15]
Bonelli P, Tuccillo FM, Borrelli A, et al. CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity[J]. Biomed Res Int, 2014:361020.
[16]
Akin S, Babacan T, Sarici F, et al. A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors[J]. J BUON, 2014, 19(1):42-46.
[17]
Hnit SS, Xie C, Yao M, et al. p27(Kip1) signaling: transcriptional and post-translational regulation[J]. Int J Biochem Cell Biol, 2015(68):9-14.
[18]
Nadeem L, Brkic J, Chen YF, et al. Cytoplasmic mislocalization of p27 and CDK2 mediates the anti-migratory and anti-proliferative effects of Nodal in human trophoblast cells[J]. J Cell Sci, 2013, 126(Pt 2):445-453.
[19]
Dai L, Liu Y, Liu J, et al. A novel cyclinE/cyclinA-CDK inhibitor targets p27(Kip1) degradation, cell cycle progression and cell survival: implications in cancer therapy[J]. Cancer Lett, 2013, 333(1):103-112.
[20]
He W, Wang X, Chen L, et al. A crosstalk imbalance between p27(Kip1) and its interacting molecules enhances breast carcinogenesis[J]. Cancer Biother Radiopharm, 2012, 27(7):399-402.
[1] 韩丹, 王婷, 肖欢, 朱丽容, 陈镜宇, 唐毅. 超声造影与增强CT对儿童肝脏良恶性病变诊断价值的对比分析[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 939-944.
[2] 娄丽丽, 刘瀚旻. 儿童狼疮性肾炎相关肾小管间质损伤的研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 373-378.
[3] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[4] 江振剑, 蒋明, 黄大莉. TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 623-626.
[5] 樊丽超, 郭瑾瑛, 陈鑫. 野生型RET与RET/PTC融合基因检测对甲状腺乳头状癌中央区淋巴结清扫的指导意义[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 631-635.
[6] 陈忠垚, 陈胜灯, 李秋. 不同手术时机对原发性肝癌自发破裂出血患者远期预后的影响[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 518-521.
[7] 孟令展, 朱震宇. 达芬奇机器人辅助肝中叶切除术[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 373-373.
[8] 唐灿, 李向阳, 秦浩然, 李婧, 王天云, 柯阳, 朱红. 原发性肝脏神经内分泌肿瘤单中心12例诊治与疗效分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 674-680.
[9] 崔佳琪, 吴迪, 陈海艳, 周惠敏, 顾元龙, 周光文, 杨军. TACE术后并发肝脓肿的临床诊治分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 688-693.
[10] 杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
[11] 韩冰, 顾劲扬. 深度学习神经网络在肝癌诊疗中的研究及应用前景[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 480-485.
[12] 何传超, 肖治宇. 晚期肝癌综合治疗模式与策略[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 486-489.
[13] 王楚风, 蒋安. 原发性肝癌的分子诊断[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 499-503.
[14] 顾娇娇, 邹燕, 陈奕辰, 黄师菊, 张慧玲, 林楠. 基于简易营养评价精法评估肝癌患者出院后营养状况及其影响因素[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 534-539.
[15] 孟令展, 李虎, 俞鹏, 于燕宾, 曹李, 翟伟, 高远, 邵艳玲, 严锦, 朱震宇. ICG荧光染色在肝癌腹腔镜解剖性肝切除术中的应用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 557-561.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号